Primary amine-containing biomolecules

Primary amine-containing biomolecules represent a diverse and essential class of biological entities characterized by the presence of a free amino group (-NH2). This category includes a wide range of molecules such as amino acids (e.g., lysine), biogenic amine neurotransmitters (e.g., dopamine, serotonin, and histamine), polyamines, and specific phospholipids like phosphatidylethanolamine. These molecules are fundamental to various biological processes, including the maintenance of protein structural integrity, the mediation of synaptic signaling in the nervous system, and the regulation of membrane fluidity and function. In clinical and pathological contexts, primary amines are the primary targets for non-enzymatic glycation by reducing sugars and reactive carbonyl species, a process that leads to the formation of Advanced Glycation End-products (AGEs) and is heavily implicated in the complications of diabetes, cardiovascular disease, and aging. From a pharmacological perspective, the high chemical reactivity of the primary amine group is extensively exploited for bioconjugation and the development of targeted therapeutics. Amine-reactive functional groups, such as N-hydroxysuccinimide (NHS) esters, are commonly used to covalently attach drugs, fluorophores, or chelators to proteins and antibodies, facilitating the creation of antibody-drug conjugates (ADCs) and molecular imaging probes. Therapeutic strategies also involve the use of carbonyl scavengers or glycation inhibitors, such as aminoguanidine and pyridoxamine, which aim to protect endogenous primary amines from deleterious modifications. However, targeting this broad class presents significant challenges, including the risk of non-specific modification of essential proteins and the potential for interfering with critical neurotransmitter pathways.

Other names

Amine-containing biomoleculesFree amine-containing moleculesBiogenic aminesPrimary amines

Drugs and reagents targeting primary amine-containing biomolecules typically act through covalent modification or by scavenging reactive species that would otherwise modify the amines. Amine-reactive reagents, such as NHS esters, undergo nucleophilic attack by the primary amine to form stable amide bonds, a process central to bioconjugation and the synthesis of antibody-drug conjugates. Glycation inhibitors and carbonyl scavengers act as sacrificial targets or protective agents to prevent the formation of advanced glycation end-products (AGEs) on endogenous proteins and lipids.